EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER

EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER

BRD2, BRD3, and BRD4 are members of the BET family of bromodomain inhibitors that have received intense current interest as novel treatments for cancer. The BET proteins function as epigenetic modulators that recognize specifically marked regions of histones and thereby influence gene transcription....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2014-11, Vol.16 (Suppl 5), p.v75-v75
Hauptverfasser: Johnstone, Shawn, Johhnsone, Andrea, Penas, Clara, Stathias, Vasileios, Brothers, Shaun, Ayad, Nagi, Wahlestedt, Claes, Albert, Jeffrey
Format: Artikel
Sprache:eng
Schlagworte:
Abstracts
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page v75
container_issue Suppl 5
container_start_page v75
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 16
creator Johnstone, Shawn
Johhnsone, Andrea
Penas, Clara
Stathias, Vasileios
Brothers, Shaun
Ayad, Nagi
Wahlestedt, Claes
Albert, Jeffrey
description BRD2, BRD3, and BRD4 are members of the BET family of bromodomain inhibitors that have received intense current interest as novel treatments for cancer. The BET proteins function as epigenetic modulators that recognize specifically marked regions of histones and thereby influence gene transcription. Numerous highly potent, highly selective BET inhibitors have emerged and some (e.g. IBET-762) have advanced to clinical trials. We aimed to develop BET inhibitors as drug for untreatable forms of brain cancer including GBM (glioblastoma multiforme) and metastatic brain cancer. Unfortunately, we found that they are poorly suited as drugs for any indications that require high CNS drug exposure because they have high susceptibility to efflux transporters and low passive cellular permeability. To improve CNS penetration, we employed a structure-based design approach that involved (1) disrupting key transporter pharmacophore points and (2) altering the physical properties to improve cellular permeability. In this manner we have identified EP11313 which has strong potency (BRD4 IC 50 7 nM), low efflux (ER
doi_str_mv 10.1093/neuonc/nou254.4
format Article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4218098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4218098</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_42180983</originalsourceid><addsrcrecordid>eNqljU1Pg0AYhDdGE-vH2ev7A6Rl-ZJeTBZ4KZvALlk2TTwRrKiYFppSTPwR_mfB9OLZ00xmMs8QckfNOTWX9qKth67dLNpusFxn7pyRGXUt23B9zzv_9Zbhu_Thklz1_YdpWtT16Ix848ownQjXmMo8Q6FBxpDwVZI-QS71GNxDgSmGmq8RAtQQKJnJSGaMC-Ai4QHXUhWgE6aBKYRQFJCjQK3YSGMiAozj036cKBlNLyMC02I6C9RECpkIUd2Qi9dq29e3J70mjzHqMDH2w_OuftnU7fFQbcv9odlVh6-yq5ryb9M27-Vb91k6FvXNpW__G_ADV0BmNw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Johnstone, Shawn ; Johhnsone, Andrea ; Penas, Clara ; Stathias, Vasileios ; Brothers, Shaun ; Ayad, Nagi ; Wahlestedt, Claes ; Albert, Jeffrey</creator><creatorcontrib>Johnstone, Shawn ; Johhnsone, Andrea ; Penas, Clara ; Stathias, Vasileios ; Brothers, Shaun ; Ayad, Nagi ; Wahlestedt, Claes ; Albert, Jeffrey</creatorcontrib><description>BRD2, BRD3, and BRD4 are members of the BET family of bromodomain inhibitors that have received intense current interest as novel treatments for cancer. The BET proteins function as epigenetic modulators that recognize specifically marked regions of histones and thereby influence gene transcription. Numerous highly potent, highly selective BET inhibitors have emerged and some (e.g. IBET-762) have advanced to clinical trials. We aimed to develop BET inhibitors as drug for untreatable forms of brain cancer including GBM (glioblastoma multiforme) and metastatic brain cancer. Unfortunately, we found that they are poorly suited as drugs for any indications that require high CNS drug exposure because they have high susceptibility to efflux transporters and low passive cellular permeability. To improve CNS penetration, we employed a structure-based design approach that involved (1) disrupting key transporter pharmacophore points and (2) altering the physical properties to improve cellular permeability. In this manner we have identified EP11313 which has strong potency (BRD4 IC 50 7 nM), low efflux (ER &lt;2), high passive cellular permeability (Papp 13.3 × 10 −6 cm/s), moderate oral bioavailability in mouse (59%) and high CNS exposure. EP11313 (after daily drug administration for 3 weeks) shows antiproliferative effects in TMZ-resistant cancer patient stem cell lines and dose-dependent tumor reduction in nu/nu mice that were centrally transplanted with luciferase-expressing GBM cell xenografts.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/nou254.4</identifier><language>eng</language><publisher>Oxford University Press</publisher><subject>Abstracts</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v75-v75</ispartof><rights>Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2014. 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218098/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218098/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Johnstone, Shawn</creatorcontrib><creatorcontrib>Johhnsone, Andrea</creatorcontrib><creatorcontrib>Penas, Clara</creatorcontrib><creatorcontrib>Stathias, Vasileios</creatorcontrib><creatorcontrib>Brothers, Shaun</creatorcontrib><creatorcontrib>Ayad, Nagi</creatorcontrib><creatorcontrib>Wahlestedt, Claes</creatorcontrib><creatorcontrib>Albert, Jeffrey</creatorcontrib><title>EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>BRD2, BRD3, and BRD4 are members of the BET family of bromodomain inhibitors that have received intense current interest as novel treatments for cancer. The BET proteins function as epigenetic modulators that recognize specifically marked regions of histones and thereby influence gene transcription. Numerous highly potent, highly selective BET inhibitors have emerged and some (e.g. IBET-762) have advanced to clinical trials. We aimed to develop BET inhibitors as drug for untreatable forms of brain cancer including GBM (glioblastoma multiforme) and metastatic brain cancer. Unfortunately, we found that they are poorly suited as drugs for any indications that require high CNS drug exposure because they have high susceptibility to efflux transporters and low passive cellular permeability. To improve CNS penetration, we employed a structure-based design approach that involved (1) disrupting key transporter pharmacophore points and (2) altering the physical properties to improve cellular permeability. In this manner we have identified EP11313 which has strong potency (BRD4 IC 50 7 nM), low efflux (ER &lt;2), high passive cellular permeability (Papp 13.3 × 10 −6 cm/s), moderate oral bioavailability in mouse (59%) and high CNS exposure. EP11313 (after daily drug administration for 3 weeks) shows antiproliferative effects in TMZ-resistant cancer patient stem cell lines and dose-dependent tumor reduction in nu/nu mice that were centrally transplanted with luciferase-expressing GBM cell xenografts.</description><subject>Abstracts</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqljU1Pg0AYhDdGE-vH2ev7A6Rl-ZJeTBZ4KZvALlk2TTwRrKiYFppSTPwR_mfB9OLZ00xmMs8QckfNOTWX9qKth67dLNpusFxn7pyRGXUt23B9zzv_9Zbhu_Thklz1_YdpWtT16Ix848ownQjXmMo8Q6FBxpDwVZI-QS71GNxDgSmGmq8RAtQQKJnJSGaMC-Ai4QHXUhWgE6aBKYRQFJCjQK3YSGMiAozj036cKBlNLyMC02I6C9RECpkIUd2Qi9dq29e3J70mjzHqMDH2w_OuftnU7fFQbcv9odlVh6-yq5ryb9M27-Vb91k6FvXNpW__G_ADV0BmNw</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Johnstone, Shawn</creator><creator>Johhnsone, Andrea</creator><creator>Penas, Clara</creator><creator>Stathias, Vasileios</creator><creator>Brothers, Shaun</creator><creator>Ayad, Nagi</creator><creator>Wahlestedt, Claes</creator><creator>Albert, Jeffrey</creator><general>Oxford University Press</general><scope>5PM</scope></search><sort><creationdate>20141101</creationdate><title>EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER</title><author>Johnstone, Shawn ; Johhnsone, Andrea ; Penas, Clara ; Stathias, Vasileios ; Brothers, Shaun ; Ayad, Nagi ; Wahlestedt, Claes ; Albert, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_42180983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnstone, Shawn</creatorcontrib><creatorcontrib>Johhnsone, Andrea</creatorcontrib><creatorcontrib>Penas, Clara</creatorcontrib><creatorcontrib>Stathias, Vasileios</creatorcontrib><creatorcontrib>Brothers, Shaun</creatorcontrib><creatorcontrib>Ayad, Nagi</creatorcontrib><creatorcontrib>Wahlestedt, Claes</creatorcontrib><creatorcontrib>Albert, Jeffrey</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnstone, Shawn</au><au>Johhnsone, Andrea</au><au>Penas, Clara</au><au>Stathias, Vasileios</au><au>Brothers, Shaun</au><au>Ayad, Nagi</au><au>Wahlestedt, Claes</au><au>Albert, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2014-11-01</date><risdate>2014</risdate><volume>16</volume><issue>Suppl 5</issue><spage>v75</spage><epage>v75</epage><pages>v75-v75</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>BRD2, BRD3, and BRD4 are members of the BET family of bromodomain inhibitors that have received intense current interest as novel treatments for cancer. The BET proteins function as epigenetic modulators that recognize specifically marked regions of histones and thereby influence gene transcription. Numerous highly potent, highly selective BET inhibitors have emerged and some (e.g. IBET-762) have advanced to clinical trials. We aimed to develop BET inhibitors as drug for untreatable forms of brain cancer including GBM (glioblastoma multiforme) and metastatic brain cancer. Unfortunately, we found that they are poorly suited as drugs for any indications that require high CNS drug exposure because they have high susceptibility to efflux transporters and low passive cellular permeability. To improve CNS penetration, we employed a structure-based design approach that involved (1) disrupting key transporter pharmacophore points and (2) altering the physical properties to improve cellular permeability. In this manner we have identified EP11313 which has strong potency (BRD4 IC 50 7 nM), low efflux (ER &lt;2), high passive cellular permeability (Papp 13.3 × 10 −6 cm/s), moderate oral bioavailability in mouse (59%) and high CNS exposure. EP11313 (after daily drug administration for 3 weeks) shows antiproliferative effects in TMZ-resistant cancer patient stem cell lines and dose-dependent tumor reduction in nu/nu mice that were centrally transplanted with luciferase-expressing GBM cell xenografts.</abstract><pub>Oxford University Press</pub><doi>10.1093/neuonc/nou254.4</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v75-v75
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4218098
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Abstracts
title EG-04DEVELOPMENT OF HIGHLY POTENT, SELECTIVE BET BROMODOMAIN INHIBITORS THAT ARE CNS PENETRANT AND EFFECTIVE IN RODENT MODELS OF BRAIN CANCER
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T08%3A48%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EG-04DEVELOPMENT%20OF%20HIGHLY%20POTENT,%20SELECTIVE%20BET%20BROMODOMAIN%20INHIBITORS%20THAT%20ARE%20CNS%20PENETRANT%20AND%20EFFECTIVE%20IN%20RODENT%20MODELS%20OF%20BRAIN%20CANCER&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Johnstone,%20Shawn&rft.date=2014-11-01&rft.volume=16&rft.issue=Suppl%205&rft.spage=v75&rft.epage=v75&rft.pages=v75-v75&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/nou254.4&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4218098%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true